NRIX
$15.48
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The ...
Recent News
Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple
Nurix Therapeutics (NRIX) has been drawing attention after recent share price swings, including a move of about 11% lower over the past month and roughly 10% lower over the past 3 months. See our latest analysis for Nurix Therapeutics. Those recent pullbacks fit into a mixed picture, with a 30 day share price return of 10.63% and a year to date share price return of an 11.57% decline, contrasting with a 1 year total shareholder return of 3.37% and a 3 year total shareholder return of 76.08%...
Nurix Therapeutics Stock Sees RS Rating Jump To 82
Nurix Therapeutics stock now meets that criteria, with a jump from 77 to 82 Wednesday. IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matches up against that of all other stocks. Is Nurix Therapeutics Stock A Buy?
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.